Receptor-mediated transport of human amyloid β-protein 1-40 and 1-42 at the blood-brain barrier

Neurobiology of Disease

Volumn 6, Issue 3, 1999, Pages 190-199

  Poduslo, Joseph F ^a   Curran, Geoffry L ^a   Sanyal, Bharati ^a   Selkoe, Dennis J ^b  

^a MAYO CLINIC   (United States)

^b Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; IODINE 125; IODINE 131;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; DIFFUSION; ENANTIOMER; NONHUMAN; PLASMA VOLUME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TRANSPORT; RAT;

EID: 0032995727     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1999.0238     Document Type: Article

References (35)

1. Akiyama H., Mori H., Sahara N., Kondo H., Ikeda K., Nishimura T., Oda T., McGeer P. L. Variable deposition of amyloid beta-protein (Aβ) with the carboxy-terminus that ends at residue valine(40) (Aβ 40) in the cerebral cortex of patients with Alzheimer's disease: A double-labeling immunohistochemical study with antibodies specific for Aβ 40 and the Aβ that ends at residues alanine(42)/threonine(43) (Aβ 42). Neurochem. Res. 22:1997;1499-1506.
2. Biere A. L., Ostaszewski B., Stimson E. R., Hyman B. T., Maggio J. E., Selkoe D. J. Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem. 271:1996;32916-32922.
3. Castano E. M., Prelli F., Soto C., Beavis R., Matsubara E., Shoji M., Frangione B. The length of amyloid-beta in hereditary cerebral hemorrhage with amyloidosis, dutch-type implications for the role of amyloid-beta 1-42 in Alzheimer's disease. J. Biol. Chem. 271:1996;32185-32191.
4. Cribbs D. H., Pike C. J., Weinstein S. L., Velazquez P., Cotman C. W. All-d-enantiomers of beta-amyloid exhibit similar biological properties to all-l-beta-amyloids. J. Biol. Chem. 272:1997;7431-7436.
5. Du Y. S., Bales K. R., Dodel R. C., Liu X. D., Glinn M. A., Horn J. W., Little S. P., Paul S. M. alpha(2)-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J. Neurochem. 70:1998;1182-1188.
6. Gravina S. A., Ho L. B., Eckman C. B., Long K. E., Otvos L., Younkin L. H., Suzuki N., Younkin S. G. Amyloid beta protein (Aβ) in Alzheimer's disease brain - Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ 40 or Aβ 42(43). J. Biol. Chem. 270:1995;7013-7016.
7. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B., Selkoe D. J. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature. 359:1992;322-325.
8. Jarrett J. T., Berger E. P., Lansbury P. T. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry. 32:1993;4693-4697.
9. Mackic J. B., Weiss M. H., Miao W., Kirkman E., Ghiso J., Calero M., Bading J., Frangione B., Zlokovic B. V. Cerebrovascular accumulation and increased blood-brain barrier permeability to circulating Alzheimer's amyloid beta peptide in aged squirrel monkey with cerebral amyloid angiopathy. J. Neurochem. 70:1998;210-215.
10. Maness L. M., Banks W. A., Podlisny M. B., Selkoe D. J., Kastin A. J. Passage of human amyloid β-protein 1-40 across the murine blood-brain barrier. Life Sci. 55:1994;1643-1650.
11. Martel C. L., Mackic J. B., McComb J. G., Ghiso J., Zlokovic B. V. Blood-brain barrier uptake of the 40 and 42 amino acid sequences of circulating Alzheimer's amyloid beta in guinea pigs. Neurosci. Lett. 206:1996;157-160.
12. Martel C. L., Ghiso J., Frangione B., Zlokovic B. V. Transport of apolipoproteins E and J at the blood-brain barrier - Relevance to Alzheimer's disease. Stp. Pharmacol. Sci. 7:1997a;28-36.
13. Martel C. L., Mackic J. B., Matsubara E., Governale S., Miguel C., Miao W., McComb J. G., Frangione B., Ghiso J., Zlokovic B. V. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J. Neurochem. 69:1997b;1995-2004.
14. Miller D. L., Papayannopoulos I. A., Styles J., Bobin S. A., Lin Y. Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301:1993;41-52.
15. Mori H., Takio K., Ogawara M., Selkoe D. J. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem. 267:1992;17082-17086.
16. Poduslo J. F. Albumin and the blood-nerve barrier. Peripheral Neuropathy. 1993;Saunders, Philadelphia. p. 446-452.
17. Poduslo J. F., Curran G. L. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc. Natl. Acad. Sci. USA. 89:1992;2218-2222.
18. Poduslo J. F., Curran G. L. Glycation increases in permeability of proteins across the blood-nerve and blood-brain barriers. Mol. Brain Res. 23:1994;157-162.
19. Poduslo J. F., Low P. A., Windebank A. J., Dyck P. J., Berg C. T., Schmelzer J. D. Altered blood-nerve barrier in experimental lead neuropathy assessed by changes in endoneurial albumin concentration. J. Neurosci. 2:1982;1507-1514.
20. Poduslo J. F., Curran G. L., Dyck P. J. Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy. Proc. Natl. Acad. Sci. USA. 85:1988;4879-4883.
21. Poduslo J. F., Curran G. L., Berg C. T. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. USA. 91:1994;5705-5709.
22. Poduslo J. F., Curran G. L., Haggard J. J., Biere A. L., Selkoe D. J. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid β-protein 1-40 at the blood-brain barrier. Neurobiol. Dis. 4:1997;27-34.
23. Poduslo J. F., Curran G. L., Kumar A., Frangione B., Soto C. β-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J. Neurobiol. 1999.
24. Prelli, Castano E., Glenner G. G., Frangione B. Differences between vascular and plaque core amyloid in Alzheimer's disease. J. Neurochem. 51:1988;648-651.
25. Roher A. E., Lowenson J. D., Clarke S., Wolkow C., Wang R., Cotter R. J., Reardon I. M., Zurcher-Neely H. A., Heinrikson R. L., Ball M. J., Greenberg B. D. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 268:1993;3072-3083.
26. Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T. D., Hardy J., Hutton M., Kukull W., Larson E., Levy-Lahad E., Viitanen M., Peskind E., Poorkaj P., Schellenberg G., Tanzi R., Wasco W., Lannfelt L., Selkoe D., Younkin S. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2:1996;864-870.
27. Selkoe D. J. Alzheimer's disease: Genotypes, phenotype, and treatments. Science. 275:1997;630-631.
28. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M., Whaley J., Swindlehurst C., McCormack R., Wolfert R., Selkoe D. J., Liederburg I., Schenk D. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature. 359:1992;325-327.
29. Shayo M., Mclay R. N., Kastin A. J., Banks W. A. The putative blood-brain barrier transporter for the beta-amyloid binding protein apolipoprotein J is saturated at physiological concentrations. Life Sci. 60:1997;PL115-PL118.
30. Shinkai Y., Yoshimura M., Ito Y., Odaka A., Suzuki N., Yanagisawa K., Ihara Y. Amyloid β-proteins 1-40 and 1-42(43) in the soluble fraction of extra- and intracranial blood vessels. Ann Neurol. 38:1995;421-428.
31. Shoji M., Golde T. J., Cheung T., Estus S., Shaffer L., Cai X.-D., Mckay D., Tintner R., Frangione B., Younkin S. Production of the Alzheimer amyloid β-protein by normal proteolytic processing. Science. 258:1992;126-129.
32. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
33. Zlokovic B. V., Ghiso J., Mackic J. B., McComb J. G., Weiss M. H., Frangione B. Blood-brain barrier transport of circulating Alzheimer's amyloid β Biochem. Biophys. Res. Commun. 197:1993;1034-1040.
34. Zlokovic B. V., Martel C. L., Mackic J. B., Matsubara E., Wisniewski T., McComb J. G., Frangione B., Ghiso J. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid β Biochem. Biophys. Res. Commun. 205:1994;1431-1437.
35. Zlokovic B. V. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: possible anti-amyloidogenic role of the blood-brain barrier. Life Sci. 59:1996;1483-1497.